This paper summarized professor XU Jingshi's understanding and clinical experience of using Zhuru （Caulis Bambusae in Taenia）. It is suggested that suitable processed products should be flexibly selected according to the pathogenesis. Ginger-fried Zhuru is good at clearing the gallbladder and harmonizing the stomach， and balancing the ascending and descending， and self-made Xiaohua Funing Decoction （消化复宁汤）， modified Huanglian Wendan Decoction （黄连温胆汤）， and Danqi Heluo Beverage （丹七和络饮） can be used to treat palpitations， restlessness， upset， insomnia， and others. Dried Zhuru can resolve phlegm and clear heat， harmonize the center and calm spirit， and self-made Qingdan Cuimian Formula （清胆催眠方） is often used to treat palpitations， restlessness， insomnia， etc. Raw Zhuru is good at clearing the lung and dispelling phlegm， relieving cough and calming panting， which is commonly used in treating phlegm-heat cough and asthma caused by phlegm heat accumulating in the lung and ascending counterflow of lung qi. In addition， as Zhuru can clear heart and remove vexation， direct counterflow downward and relieve constraint， self-made Shugan Liyu Formula （疏肝理郁方） is often used to treat all diseases caused by constraints. Considering Zhuru has the function of harmonizing the actions of all medicinals in a formula， guiding the medicinals into the stomach， and regulating the ascending and descending of qi movement in central spleen and stomach， self-made Fuzheng Anzhong Decoction （扶正安中汤） can be used for postoperative treatment of various malignant tumors.

The use of checkpoint-blockade antibodies is still restricted in several malignancies due to the modest efficacy, despite considerable success in anti-tumor immunotherapy. The poor response of cancer cells to immune destruction is an essential contributor to the failure of checkpoint therapy. We hypothesized that combining checkpoint therapy with natural-product chemosensitizer could enhance immune response. Herein, a targeted diterpenoid derivative was integrated with the checkpoint blockade (anti-CTLA-4) to improve immunotherapy using thermosensitive liposomes as carriers. In vivo, the liposomes enabled the co-delivery of the two drug payloads into the tumor. Consequently, the regulatory T cell proliferation was restrained, the cytotoxic T cell infiltration was enhanced, and the profound immunotherapeutic effect was achieved. In addition, the immunotherapeutic effect of another clinically used checkpoint antibody, anti-PD-1, also benefited from the diterpenoid derivative. Of note, our mechanism study revealed that the targeted diterpenoid derivative increased the sensitivity of cancer cells to immune attack via THBS1 downregulation and the resultant destruction of THBS1-CD47 interaction. Collectively, co-delivering THBS1 inhibitor and checkpoint blockade is promising to boost cancer immunotherapy. We first time discovered that THBS1 suppression could strengthen checkpoint therapy.